Interazioni tra farmaci
Clomipramine + Dacomitinib
Gravità: Maggiore
Clomipramine and Dacomitinib: major interaction.
Ultimo aggiornamento
Per operatori sanitari — solo a scopo di riferimento. Questa pagina è una sintesi breve, non è un parere medico e non sostituisce il RCP ufficiale né il giudizio clinico. Verificare sempre prima di prescrivere o dispensare.
Il contenuto clinico di questa pagina è disponibile solo in inglese.
Sintesi
Dacomitinib is a strong inhibitor of CYP2D6, an enzyme that contributes to clomipramine clearance, particularly of its active metabolite pathway. Clomipramine exposure may rise, increasing anticholinergic effects, sedation, seizure risk and cardiac conduction toxicity.
Cosa significa questa interazione in parole semplici
Clomipramine and Dacomitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Clomipramine belongs to Central Nervous System; Dacomitinib belongs to Oncology.
Perché avviene
Dacomitinib inhibits CYP2D6, reducing the hydroxylation and clearance of clomipramine.
Cosa fare
Consider an alternative to one of the drugs; if combined, start clomipramine at a low dose and titrate to response. Monitor for tricyclic toxicity and consider ECG and plasma level monitoring.
Cosa chiedere al farmacista
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Per gli utenti Pro+
Sblocca la pagina completa
Crei un account e avvii una prova di Pro+ per sbloccare le indicazioni complete sulla gestione di Clomipramine e Dacomitinib, le note aggiuntive, il dettaglio delle evidenze e il controllo delle interazioni per un'intera prescrizione.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Provi Pro+ gratis per 14 giorni sul web. Nessuna carta.
Altre interazioni di Clomipramine
- Arsenic trioxide + Clomipramine Controindicata
- Clomipramine + Dofetilide Controindicata
- Clomipramine + Droperidol Controindicata
- Clomipramine + Isocarboxazid Controindicata
- Clomipramine + Methylene blue Controindicata
- Clomipramine + Pentamidine Controindicata
Altre interazioni di Dacomitinib
- Dacomitinib + Thioridazine Controindicata
- Amitriptyline + Dacomitinib Maggiore
- Atomoxetine + Dacomitinib Maggiore
- Brexpiprazole + Dacomitinib Maggiore
- Dacomitinib + Desipramine Maggiore
- Dacomitinib + Dexlansoprazole Maggiore
Domande frequenti
Can I take Clomipramine with Dacomitinib?
MediHelp rates the interaction as major. Clomipramine and Dacomitinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Dacomitinib is a strong inhibitor of CYP2D6, an enzyme that contributes to clomipramine clearance, particularly of its active metabolite pathway. Clomipramine exposure may rise, increasing anticholinergic effects, sedation, seizure risk and cardiac conduction toxicity.
How serious is the interaction between Clomipramine and Dacomitinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Consider an alternative to one of the drugs; if combined, start clomipramine at a low dose and titrate to response. Monitor for tricyclic toxicity and consider ECG and plasma level monitoring.
What other medicines interact with Clomipramine?
MediHelp also lists interactions of Clomipramine with, for example, Arsenic trioxide, Dofetilide, Droperidol. The full list is on the Clomipramine page.
Monografie complete, posologie e verifica delle interazioni nell'app MediHelp
Apra il riferimento completo, verifichi le interazioni tra più farmaci e usi gli strumenti di posologia nell'app MediHelp.
